Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2016
Harnessing the U.S. taxpayer to fight cancer and make profits
19 December 2016 - Enthusiasm for cancer immunotherapy is soaring, and so is Arie Belldegrun’s fortune. ...
Posted by Michael Wonder on 15 Dec 2016
A new type of molecular medicine may be needed to halt cancers
16 December 2016 - Doctors must look to proteins rather than genes to tackle tumours. ...
Posted by Michael Wonder on 14 Dec 2016
Obama signs $6.3 billion law for cancer research, drug treatment
14 December 2016 - President Barack Obama has signed into law legislation that makes new investments in cancer research and battling ...
Posted by Michael Wonder on 13 Dec 2016
We need to tame the price of new cancer drugs
13 December 2016 - Last week Dr. Peter Bach, a physician and cancer drug pricing theorist, gave a plenary lecture ...
Posted by Michael Wonder on 08 Dec 2016
1 patient, 7 tumours and 100 billion cells equal 1 striking recovery
7 December 2016 - The remarkable recovery of a woman with advanced colon cancer, after treatment with cells from her ...
Posted by Michael Wonder on 04 Dec 2016
Immune system, unleashed by cancer therapies, can attack organs
3 December 2016 - As Chuck Peal lay in a Waterbury, Connecticut, emergency room one Sunday in early September, doctors ...
Posted by Michael Wonder on 02 Dec 2016
Cancer drugs may remain approved despite lack of benefit
1 December 2016 - In the United States, cancer drugs are sometimes approved through sped-up processes - and they often ...
Posted by Michael Wonder on 29 Nov 2016
Improving the accelerated pathway to cancer drug approvals
29 November 2016 - The US FDA must balance the need to bring potentially lifesaving drugs to market with the need ...
Posted by Michael Wonder on 29 Nov 2016
Cancer immunology community seeks better end points
29 November 2016 - Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint ...
Posted by Michael Wonder on 25 Oct 2016
FDA approves Merck’s Keytruda (pembrolizumab) in metastatic NSCLC for first-line treatment of patients whose tumours have high PD-L1 expression (tumour proportion score of 50 percent or more) with no EGFR or ALK genomic tumour aberrations
25 October 2016 - FDA also approves a labeling Update for Keytruda for the treatment of patients with metastatic NSCLC ...
Posted by Michael Wonder on 24 Oct 2016
FDA approves supplemental new drug application for Xtandi in advanced prostate cancer
24 October 2016 - Astellas and Pfizer today announced the U.S. FDA approved a supplemental new drug application to update the ...
Posted by Michael Wonder on 18 Oct 2016
Time to reassess the cancer compendia for off-label drug coverage in oncology
18 October 2016 - Use of cancer therapies for indications not approved by the US FDA, also known as “off-label” use, ...
Posted by Michael Wonder on 04 Oct 2016
US FDA grants breakthrough therapy designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
4 October 2016 - This second Alecensa breakthrough therapy designation granted is based on phase 3 J-ALEX study. ...
Posted by Michael Wonder on 26 Sep 2016
AbbVie announces submission of a supplemental new drug application for Ibrutinib (imbruvica) for treatment of marginal zone lymphoma
26 September 2016 - If approved by the U.S. FDA, ibrutinib will be the first therapy specifically approved for patients with ...
Posted by Michael Wonder on 21 Sep 2016
Evaluating the FDA’s approach to cancer clinical trials
16 September 2016 - Since the announcement of the FDA Oncology Center of Excellence in June 2016 as part of the ...